trastuzumab deruxtecan shows benefit in patients with her2 mbc
Published 1 year ago • 316 plays • Length 5:26Download video MP4
Download video MP3
Similar videos
-
5:09
trastuzumab deruxtecan shows benefit across her2 metastatic breast cancer subgroups
-
12:47
trastuzumab deruxtecan vs trastuzumab emtansine in patients with her2 metastatic breast cancer
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
3:45
trastuzumab-deruxtecan: a game-changer in her2-positive cancers │ pharmacology
-
9:05
pertuzumab plus trastuzumab and chemotherapy continues to show benefit in her2-positive breast c...
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
2:06
trastuzumab deruxtecan for breast cancer | nejm
-
20:11
her2-positive breast cancer—reduce your risk of recurrence | access health
-
5:05
anti-her2 mechanisms of approved her2 inhibitors
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
0:59
trastuzumab deruxtecan in patients with breast cancer with brain metastases
-
7:32
trastuzumab deruxtecan yields promising results in her2-positive breast cancer patients pretreat...
-
5:57
phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer patients
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
4:52
neratinib fulvestrant trastuzumab for hr her2-mutant mbc and neratinib trastuzumab for tr...
-
3:36
datopotamab deruxtecan extends pfs vs chemo for hr /her2- breast cancer
-
1:17
comment: phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer pts
-
7:50
could trastuzumab deruxtecan become the new standard of care for pretreated her2-positive breast...
-
7:30
#esmo21 expert video report on her2-positive metastatic breast cancer
-
5:59
trastuzumab deruxtecan for the treatment of her2 breast cancer
-
1:50
findings of a biosimilar trastuzumab study in patients with her2-positive breast cancer
-
1:21
dr. park on the benefit of trastuzumab deruxtecan in her2 breast cancer